Journal Articles

  • Mast cell activation contributes to sickle cell pathobiology and pain in mice BLOOD Vincent, L., Vang, D., Nguyen, J., Gupta, M., Luk, K., Ericson, M. E., Simone, D. A., Gupta, K. 2013; 122 (11): 1853-1862


    Sickle cell anemia (SCA) is an inherited disorder associated with severe lifelong pain and significant morbidity. The mechanisms of pain in SCA remain poorly understood. We show that mast cell activation/degranulation contributes to sickle pain pathophysiology by promoting neurogenic inflammation and nociceptor activation via the release of substance P in the skin and dorsal root ganglion. Mast cell inhibition with imatinib ameliorated cytokine release from skin biopsies and led to a correlative decrease in granulocyte-macrophage colony-stimulating factor and white blood cells in transgenic sickle mice. Targeting mast cells by genetic mutation or pharmacologic inhibition with imatinib ameliorates tonic hyperalgesia and prevents hypoxia/reoxygenation-induced hyperalgesia in sickle mice. Pretreatment with the mast cell stabilizer cromolyn sodium improved analgesia following low doses of morphine that were otherwise ineffective. Mast cell activation therefore underlies sickle pathophysiology leading to inflammation, vascular dysfunction, pain, and requirement for high doses of morphine. Pharmacological targeting of mast cells with imatinib may be a suitable approach to address pain and perhaps treat SCA.

    View details for DOI 10.1182/blood-2013-04-498105

    View details for Web of Science ID 000324570900008

    View details for PubMedID 23775718

  • Biomarkers and Electrocardiographic Evidence of Myocardial Ischemia in Patients With Human Immunodeficiency Virus Infection AMERICAN JOURNAL OF CARDIOLOGY Gupta, M., Miller, C. J., Baker, J. V., Lazar, J., Bogner, J. R., Calmy, A., Soliman, E. Z., Neaton, J. D. 2013; 111 (5): 760-764


    We assessed the relation of inflammatory and coagulation biomarkers with electrocardiographic (ECG) evidence of myocardial ischemia. High-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer levels were measured at study entry for 3,085 human immunodeficiency virus-infected participants (mean age 44 years; 26.4% women; 24.6% black) in the Strategies for Management of Antiretroviral Therapy trial. Logistic regression models were used to examine the associations of these biomarkers with prevalent and incident myocardial ischemia. The latter analyses were performed for 1,411 participants who were randomly assigned to receive continuous antiretroviral therapy during follow-up to suppress the human immunodeficiency virus viral load and had ?1 ECG reading during the follow-up period. The median hsCRP, IL-6, and D-dimer level was 1.65 ?g/ml (interquartile range 0.69 to 4.11), 1.60 pg/ml (interquartile range 1.00 to 2.75), and 0.18 ?g/ml (interquartile range 0.11 to 0.32), respectively. At baseline, the prevalence of major or minor Q-QS or ST-T ECG abnormalities was 18.6%. The biomarker levels were associated with prevalent major or minor ischemic abnormalities on the univariate analyses; however, adjustment for traditional risk factors attenuated these associations. The adjusted odds ratio for major or minor ischemic abnormalities and 95% confidence intervals for the greatest versus lowest quartiles was 1.3 (95% confidence interval 0.9 to 1.7) for hsCRP, 1.0 (95% confidence interval 0.7 to 1.3) for IL-6, and 1.1 (95% confidence interval 0.9 to 1.5) for D-dimer. During a median follow-up of 2.3 years, new definite or probable ischemic ECG abnormalities developed in 11.7% of participants receiving continuous antiretroviral therapy. Biomarker levels were not associated with incident abnormalities on unadjusted or adjusted analyses. In conclusion, higher levels of hsCRP, IL-6, and D-dimer were not associated with ischemic ECG abnormalities. Elevated biomarker levels and ECG abnormalities indicating myocardial ischemia might reflect different risk pathways for cardiovascular disease.

    View details for DOI 10.1016/j.amjcard.2012.11.032

    View details for Web of Science ID 000315666600022

    View details for PubMedID 23276469

  • Why HIV, Why Now? An Assessment of HIV Testing at the Cambridge Health Alliance (Poster) 4th Annual Cambridge Health Alliance Academic Poster Session Gupta M, Waggett J, Laforest M, Coste G, Moschella J 2010
  • A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer SCIENCE Starr, T. K., Allaei, R., Silverstein, K. A., Staggs, R. A., Sarver, A. L., Bergemann, T. L., Gupta, M., O'Sullivan, M. G., Matise, I., Dupuy, A. J., Collier, L. S., Powers, S., Oberg, A. L., Asmann, Y. W., Thibodeau, S. N., Tessarollo, L., Copeland, N. G., Jenkins, N. A., Cormier, R. T., Largaespada, D. A. 2009; 323 (5922): 1747-1750


    Human colorectal cancers (CRCs) display a large number of genetic and epigenetic alterations, some of which are causally involved in tumorigenesis (drivers) and others that have little functional impact (passengers). To help distinguish between these two classes of alterations, we used a transposon-based genetic screen in mice to identify candidate genes for CRC. Mice harboring mutagenic Sleeping Beauty (SB) transposons were crossed with mice expressing SB transposase in gastrointestinal tract epithelium. Most of the offspring developed intestinal lesions, including intraepithelial neoplasia, adenomas, and adenocarcinomas. Analysis of over 16,000 transposon insertions identified 77 candidate CRC genes, 60 of which are mutated and/or dysregulated in human CRC and thus are most likely to drive tumorigenesis. These genes include APC, PTEN, and SMAD4. The screen also identified 17 candidate genes that had not previously been implicated in CRC, including POLI, PTPRK, and RSPO2.

    View details for DOI 10.1126/science.1163040

    View details for Web of Science ID 000264559800045

    View details for PubMedID 19251594

  • AIDS at the Margin: Experiences and Lessons from Marginalized Groups in India (Part 2) The National Medical Journal of India Gupta M 2009; 22 (3): 98-100
  • AIDS at the Margin: Experiences and Lessons from Marginalized Groups in India (Part 1) The National Medical Journal of India Gupta M 2009; 22 (2): 47-49
  • Opioids as Promoters and Regulators of Angiogenesis Angiogenesis: Basic Science and Clinical Applications, Eds Maragoudakis ME and Papadimitriou E Gupta M, Li Y, Gupta K 2007: 303-318

Stanford Medicine Resources: